Loading...
In the ROCKET AF trial, rivaroxaban (20 mg) was noninferior to adjusted-dose warfarin for prevention of thromboembolic events in 14,264 patients with atrial fibrillation (NEJM JW Cardiol Aug 10 2011). In a prespecified subanalysis, investigators compared the efficacy and safety of rivaroxaban versus warfarin among patients who had been taking vitamin K antagonists (VKAs) for ≥6 weeks at screening (55%) and those who had not (45%).
At baseline, VKA-experienced patients were older, were less likely to be women, had lower blood pressure, and had lower CHADS2 scores than VKA-naive patients. During approximately 2 years of follow-up, nearly one quarter of patients discontinued study treatment. Stroke and cardiovascular event rates were lower in t…